VAXinia (CF33-hNIS) / Imugene 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
VAXinia (CF33-hNIS) / Imugene
NCT05081492: CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Active, not recruiting
1
9
US
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody, CF33 Expressing hNIS-Anti-PD-L1 Antibody, CF33-hNIS-antiPDL1
City of Hope Medical Center, National Cancer Institute (NCI), Imugene Limited
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
09/24
09/24
OASIS, NCT06063317: A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1
52
US
CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto
Imugene Limited
Solid Tumor, Adult
09/24
09/25
MAST, NCT05346484: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

Recruiting
1
100
US, RoW
CF33-hNIS, VAXINIA, HOV2, Pembrolizumab, KEYTRUDA®
Imugene Limited
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
12/24
01/25

Download Options